The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
But the one share pushed us up to 3.50 :)
Very intrigued about tomorrow's news
Welcome to the board JJNess
I don't think many investors have even heard of Faron Pharmaceuticals hence the low volume. However, it has given us all opportunities to top up at what we wil look back on as a really cheap price... hopefully
Final top up date!
Just watched the interview.. came to an end at 22 minutes.. seemed like it was cut off early.
Anyone know if it was longer?
Thanks for the link Heikkinen,
Are they saying that a partnership or a buyout is possible in 2024 depending on data over the next few months?
Happy for AW to leave.. on linked in she is on too many BOD and seems to move around alot..
Maybe she had become a bit of dead wood and was asked to leave..
Our 2 other board members are more invested so all good news
Just seen the news... Great news at that!
This is interesting video how big pharma works when their patents are running out.
https://youtu.be/VnL7XWH8uoA
Now apply this idea to the bexmab study
Bexmarilimab with Pembrolizumab which is marketed as Keytruda is on schedule to lose its patent protection in 2028
Only 5 years time! And it's making a ton of money
Heading in the right direction
Excellent.. closed 3.10 on google
Google has hit 3 quid!
293 on Google
Let's smash 300
290 on Google
Would it
T if we breached 3 quid
Anticipated for H1 2025
Thats only 18 months !
"A BLA is submitted after an investigational new drug has been approved. If the Form 356h is missing information, the FDA will reply within 74 days. A BLA asserts that the product is "safe, pure, and potent", the manufacturing facilities are inspectable, and each package of the product bears the license number."
Who owns azacitidine?
Bristol Myers Squibb
What price would they pay for bexmarilimab?
Ood news when you see they are hitting their objective response (OR) which are..
complete recovery (CR)
Maintained complete recovery (MCR)
Bearing mind the below from a Google search:
"What are the survival rates of azacitidine?
Among 488 patients with newly diagnosed AML, median overall survival was 10.4 months for those receiving azacitidine (Vidaza) "
Bex looks like it actually makes azacitidine work!
The guy who sold up before placing news.. obviouly leak.. Will he buy back in!
Someone is selling up?!?
Https://www.aiforia.com/blog/spatial-biology-cancer-research